AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 1 - (NewsRx.com & NewsRx.net) -- Ovarian cancer cells regain more normal phenotypes after simultaneous therapy.
"Coexpression of epidermal growth factor receptor (EGFR) and c-erbB-2 in 47 - 68% of ovarian cancer cells indicate their strong association with tumor formation. We examined the effects of simultaneous antisense- or immunosuppression of EGFR and c-erbB-2 expression on the invasive phenotype, aneuploidy, and genotype of cultured human ovarian carcinoma cells (NIH:OVCAR-8)," said U.S. government investigators.
"We report here that suppression of both EGFR and c-erbB-2 results in regression of aneuploidy and genomic imbalances in NIH:OVCAR-8 cells, restores a more normal phenotype, and results in a more normal gene expression profile," wrote S.D. Pack and colleagues, U.S. National Cancer Institute, NIH.
"Combined with cytogenetic analysis, our data demonstrate that the regression of aneuploidy is due to the selective apoptosis of double antisense ...
Source: HighBeam Research, Ovarian cancer cells regain more normal phenotypes with simultaneous...